These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20874044)

  • 21. Coming therapies: abacavir.
    Staszewski S
    Int J Clin Pract Suppl; 1999 Jun; 103():35-8. PubMed ID: 10622042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
    Kessler HA; Johnson J; Follansbee S; Sension MG; Mildvan D; Sepulveda GE; Bellos NC; Hetherington SV
    Clin Infect Dis; 2002 Feb; 34(4):535-42. PubMed ID: 11797183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
    Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
    Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir and cardiovascular risk.
    Behrens GM; Reiss P
    Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV exposure through contact with body fluids.
    Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB; Katzenstein TL; Gerstoft J; Mathiesen LR; Pedersen C; Nielsen C
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment options for lipodystrophy in HIV-positive patients.
    Behrens GM
    Expert Opin Pharmacother; 2008 Jan; 9(1):39-52. PubMed ID: 18076337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
    Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
    Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS
    HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.